The Committee for Medicinal Products for Human Use of the European Medicines Agency (EMA) began, on Wednesday 18 May, the formal scientific evaluation phase of the SARS-CoV vaccine developed by the firm Valneva, VLA200. The company was able to apply for a conditional marketing authorisation for its vaccine for adults aged 18 to 55.
This inactivated, adjuvanted whole virus Covid-19 vaccine, developed by Valneva, has been undergoing a progressive evaluation since 2 December 2021 (see EUROPE...